Tumor Biology

, Volume 37, Issue 1, pp 823–828 | Cite as

RETRACTED ARTICLE: The critical role of HMGA2 in regulation of EMT in epithelial ovarian carcinomas

  • Junyuan Yan
  • Yanling Zhang
  • Wenshuang Shi
  • Cuili Ren
  • Yan Liu
  • Yunyan Pan
Original Article


The high mobility group A2 (HMGA2), an oncofetal protein, was shown to play a role in tumor development and progression. However, the molecular and clinical role of HMGA2 in epithelial ovarian carcinomas (EOCs) is still unknown. In the present study, EOC cell line SKOV3 was subjected to in vitro assays. Here, our findings showed that HMGA2 was highly expressed in EOC cell line SKOV3. HMGA2 knockdown promoted cell apoptosis and the cleavage of caspase 3, and decreased the B cell lymphoma 2 (Bcl-2)/Bax ratio in SKOV3. Functionally, HMGA2 knockdown resulted in reduction of SKOV3 cell migration and invasion. Mechanically, HMGA2 knockdown affected the occurrence of EMT by increasing E-cadherin gene and protein expression and decreasing the gene and protein expression of N-cadherin, slug, and vimentin. At the same time, HMGA2 also repressed the expression of matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9 (MMP9), which was consistent with the decreased invasion capacity. In conclusion, HMGA2 is associated with migration and invasiveness and regulates the progression of EMT in the development of EOC, and HMGA2 gene and protein may be a novel therapeutic target against EOC in the clinical practice.


HMGA2 Epithelial ovarian carcinomas EMT 



We greatly thank other members of Yang Lab for valuable suggestions and writing.

Conflicts of interest



  1. 1.
    Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;S0140–6736:62146–7.Google Scholar
  2. 2.
    Harter P, Hilpert F, Mahner S, Heitz F, Pfisterer J, du Bois A. Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. Expert Rev Anticancer Ther. 2010;10:81–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Gynecologic Oncology Group Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.CrossRefPubMedGoogle Scholar
  4. 4.
    Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.CrossRefPubMedGoogle Scholar
  5. 5.
    Chiappetta G, Ammirante M, Basile A, et al. The antiapoptotic protein BAG3 is expressed in thyroid carcinomas and modulates apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Clin Endocrinol Metab. 2007;92:1159–63.CrossRefPubMedGoogle Scholar
  6. 6.
    Gentilella A, Passiatore G, Deshmane S, et al. Activation of BAG3 by Egr-1 in response to FGF-2 in neuroblastoma cells. Oncogene. 2008;27:5011–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Staibano S, Mascolo M, Benedetto M, et al. BAG3 protein delocalization in prostate carcinoma. Tumor Biol. 2010;31:461–9.CrossRefGoogle Scholar
  8. 8.
    Wang HQ, Meng X, Gao Y-Y, et al. Characterization of BAG3 cleavage during apoptosis of pancreatic cancer cells. J Cell Physiol. 2010;224:94–100.PubMedGoogle Scholar
  9. 9.
    Suzuki M, Iwasaki M, Sugio A, et al. BAG3 (BCL2-associated athanogene 3) interacts with MMP-2 to positively regulate invasion by ovarian carcinoma cells. Cancer Lett. 2011;303:65–71.CrossRefPubMedGoogle Scholar
  10. 10.
    Festa M, Del Valle L, Khalili K, et al. BAG3 protein is overexpressed in human glioblastoma and is a potential target for therapy. Am J Pathol. 2011;178:2504–12.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Rosati A, Graziano V, De Laurenzi V, et al. BAG3: a multifaceted protein that regulates major cell pathways. Cell Death Dis. 2011;7:141.CrossRefGoogle Scholar
  12. 12.
    Falco A, Festa M, Basile A, et al. BAG3 controls angiogenesis through regulation of ERK phosphorylation. Oncogene. 2012;31:5153–61.CrossRefPubMedGoogle Scholar
  13. 13.
    Li N, Du ZX, Zong ZH, et al. PKC[delta]-mediated phosphorylation of BAG3 at Ser187 site induces epithelial-mesenchymal transition and enhances invasiveness in thyroid cancer FRO cells. Oncogene. 2012;32:4539–48.CrossRefPubMedGoogle Scholar
  14. 14.
    He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353:1124–34.CrossRefPubMedGoogle Scholar
  15. 15.
    Pang RC, Joh J, Johnson P, et al. Biology of hepatocellular carcinoma. Ann Surg Oncol. 2008;15:962–71.CrossRefPubMedGoogle Scholar
  16. 16.
    Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002;8:S62–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Déry M-AC, Michaud MD, Richard DE. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol. 2005;37:535–40.CrossRefPubMedGoogle Scholar
  18. 18.
    De A, De A, Papasian C, et al. Extract induces autophagy and inhibits human ovarian cancer cell proliferation, angiogenesis, growth of mouse xenograft tumors. PLoS One. 2013;8:e72748.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kim KW, Paul P, Qiao J, et al. Enhanced autophagy blocks angiogenesis via degradation of gastrin-releasing peptide in neuroblastoma cells. Autophagy. 2013;9:1579–90.CrossRefPubMedGoogle Scholar
  20. 20.
    Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell inter-actions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 1993;9:541–73.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Junyuan Yan
    • 1
  • Yanling Zhang
    • 2
  • Wenshuang Shi
    • 2
  • Cuili Ren
    • 2
  • Yan Liu
    • 1
  • Yunyan Pan
    • 1
  1. 1.Department of Gynaecology and ObstetricsAffiliated Hospital of Shandong Academy of Medical SciencesJinanChina
  2. 2.Department of Gynaecology and ObstetricsThe Third People’s Hospital of Jinan CityJinanChina

Personalised recommendations